Concord Biotech Ratios

Concord Biotech Ltd Ratios

The Concord Biotech Ltd Ratios page provides a complete fundamental analysis of Concord Biotech Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Concord Biotech Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Concord Biotech Ltd (NSE: CONCORDBIO, BSE: 543960) is currently trading at ₹1092.30, with a market capitalization of ₹114.29B. As a major player in the Commercial services sector and Miscellaneous commercial services industry, Concord Biotech Ltd remains a key stock for fundamental analysis using Concord Biotech Ltd Ratios.

Concord Biotech Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Concord Biotech Ltd P/E ratio currently stands at 47.19, making it one of the most tracked metrics in Concord Biotech Ltd Ratios.

Historically, the Concord Biotech Ltd P/E ratio has shown strong fluctuations:

• 2024: 47.19
• 2023: 51.68
• 2022: 0
• 2021: 0
• 2020: 0

The decline in Concord Biotech Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Concord Biotech Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 9.67.

Historical P/B trend:

• 2024: 9.67
• 2023: 10.43
• 2022: 0
• 2021: 0

Concord Biotech Ltd is trading at a premium to its book value, indicating strong market confidence.

Price to Sales Ratio (P/S)

The Concord Biotech Ltd P/S ratio currently stands at 14.86, an important part of Concord Biotech Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 14.86
• 2023: 15.95
• 2022: 0
• 2021: 0

A stable or declining Concord Biotech Ltd P/S ratio indicates cautious market sentiment.

Concord Biotech Ltd Price to Cash Flow Ratio (P/CF)

The Concord Biotech Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 70.88.

Historical Concord Biotech Ltd Price to Cash Flow Ratio:

• 2024: 70.88
• 2023: 59.54
• 2022: 0
• 2021: 0
• 2020: 0

The rising Concord Biotech Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.

Concord Biotech Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Concord Biotech Ltd EV currently stands at ₹172.23B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 172.23B
• 2023: 156.41B
• 2022: 0
• 2021: 0

Concord Biotech Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.

EV/EBITDA Ratio

The Concord Biotech Ltd EV/EBITDA ratio is currently 34.74, a key metric in Concord Biotech Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 34.74
• 2023: 37.31
• 2022: 0
• 2021: 0

Stable Concord Biotech Ltd EV/EBITDA indicates balanced valuation.

Concord Biotech Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Concord Biotech Ltd D/E ratio is currently 0, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0
• 2023: 0.01
• 2022: 0.02
• 2021: 0.06

Concord Biotech Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Concord Biotech Ltd ROE currently stands at 22.26%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 22.26
• 2023: 21.88
• 2022: 20.06
• 2021: 16.64

Concord Biotech Ltd demonstrates strong profitability and efficient capital utilization.

Concord Biotech Ltd Ratios Analysis Summary

The Concord Biotech Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Concord Biotech Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Concord Biotech Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.